Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development |
| |
| Institution: | 1. Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, WA, United States;2. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, United States;3. University of Washington, Department of Medicine, Seattle, WA, United States;4. World Health Organization, Department of Reproductive Health and Research, Geneva, Switzerland;1. World Health Organization, Geneva, Switzerland;2. World Health Organization, Geneva, Switzerland;3. World Health Organization, Geneva, Switzerland;4. Mayo Clinic, Rochester, MN, USA;1. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA;2. MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK;3. Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland;1. Edith Cowan University, Joondalup, Western Australia, Australia;2. Murdoch University, Murdoch, Western Australia, Australia;3. PathWest Laboratory Medicine, Nedlands, Western Australia, Australia;4. Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia;5. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Sir Graham Davies Building, University Place, University of Glasgow, Glasgow G12 8TA, United Kingdom;1. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Lane Building L-135, Stanford, CA 94305-5107, USA;2. Stanford University, 450 Serra Mall, Stanford, CA 94305, USA;3. Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue CHS 37-121, Los Angeles, CA 90095-1688, USA;1. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4027, USA;2. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA;3. Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA;4. Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, and Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa;5. Department of Pediatrics, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA;6. Bill & Melinda Gates Foundation, Seattle, WA 98109, USA;7. MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK;8. Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland;1. Department of Microbiology, Immunology & Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;2. Vaccine Research Laboratory, UBC Centre for Disease Control, University of British Columbia, Vancouver, BC V5Z 4R4, Canada;3. Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA 92697, USA;4. Department of Pediatrics, University of North Carolina–Chapel Hill, Chapel Hill, NC 27599-7509, USA;5. Division of Microbiology and Infectious Diseases, NIAID, Bethesda, MD, USA |
| |
| Abstract: | Development of a safe and effective vaccine against herpes simplex virus type 2 (HSV-2) has the potential to limit the global burden of HSV-2 infection and disease, including genital ulcer disease and neonatal herpes, and is a global sexual and reproductive health priority. Another important potential benefit of an HSV-2 vaccine would be to decrease HIV infections, as HSV-2 increases the risk of HIV-1 acquisition several-fold. Acute and chronic HSV-2 infection creates ulcerations and draws dendritic cells and activated CD4+ T cells into genital mucosa. These cells are targets for HIV entry and replication. Prophylactic HSV-2 vaccines (to prevent infection) and therapeutic vaccines (to modify or treat existing infections) are currently under development. By preventing or modifying infection, an effective HSV-2 vaccine could limit HSV-associated genital mucosal inflammation and thus HIV risk. However, a vaccine might have competing effects on HIV risk depending on its mechanism of action and cell populations generated in the genital mucosa. In this article, we review biologic interactions between HSV-2 and HIV-1, consider HSV-2 vaccine development in the context of HIV risk, and discuss implications and research needs for future HSV vaccine development. |
| |
| Keywords: | HSV vaccine HIV Sexually transmitted infection |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
